bioLeads collaborats with Biofrontera Pharmaceuticals AG
Biofrontera’s proprietary technology platform will be utilized to identify and validate active and bioavailable compounds whilst bioLeads will provide its unique microbial chemical entity li-braries, plant derived compounds and bioassay-screening platform. Biofrontera’s expression profiling engine will then be used to substantiate these lead compounds in terms of target selectivity, biological activity profile and time course of action. Further iterative rounds of testing at bioLeads and Biofrontera will then lead to drug candidates to be licensed out to global industrial partners or to be brought to the market by the two partners themselves.
This partnership will not only synergistically combine the core strengths of bioLeads and Biofrontera, but will also permit both parties to maintain and expand their present collabora-tions with other pharmaceutical partners.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.